edward bastyr iii, M.d.
Chief Medical Officer
Dr. Bastyr serves as the Chief Medical Officer of Housey Healthcare, Inc. (HHI). He is Board Certified in Internal Medicine and Endocrinology Diabetes and Metabolism by the American Board of Internal Medicine.
Prior to joining HHI, Dr. Bastyr served as Vice President Medical of MB2 LLC, a small biopharma company engaged in the development of peptides with specific binding to glucagon inhibitory peptide (GIP), glucagon like peptide -1 (GLP-1 ) and glucagon (GCG) for the treatment of diabetes. During his tenure at MB2 he led the clinical development of two new molecular entities for the treatment of diabetes, resulting in the successful sale and transfer of these compounds to Novo Nordisk.
Before serving as Vice President Medical of MB2, Dr. Bastyr spent nearly 20 years at Lilly Research Laboratories (LRL), Eli Lilly & Co. (“Lilly”; Indianapolis, IN). He held various positions in drug development in LRL and was involved in the design and implementation of numerous clinical trials utilizing innovative methods and creative concepts for the treatment of diabetes and its complications, including the successful registration of dulaglutide (Trulicity®) based upon the clinical plan developed and negotiated with regulatory agencies in the United States and Europe. His work at Lilly was recognized with the President’s Recognition Award for Outstanding Scientific Achievement (Top 1% Scientist Award) in 2002, 2009 and 2014.
Dr. Bastyr received his Baccalaureate degree in Biochemistry from Columbia College, Columbia University, a Master of Science degree in Biochemistry from the University of Chicago and his M.D. degree from Universidad De Navarra in Spain. He trained in Internal Medicine at the University of Pittsburgh Mercy Hospital and Endocrinology at the University of Michigan Medical Center prior to his appointment to faculty positions at the University of Texas Medical Branch and Indiana University School of Medicine. He has published more than 150 abstracts and manuscripts in diabetes peer reviewed publications.
